Target
pazopanib
8 abstracts
Abstract
Results of a randomized phase II trial of 2nd-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib: Japan Clinical Oncology Group study JCOG1802 (2ND-STEP).Org: Fukui University School of Medicine,
Abstract
A multicohort platform trial to improve drug access for pediatric cancer patients in Japan: The PARTNER trial (NCCH2220).Org: Department of Pediatric Oncology,
Abstract
Prevalence of polypharmacy, drug-drug interactions, and inappropriate prescription in elderly patients with urological cancers.Org: Hospital Universitario Marques Valdecilla, HUMV,
Abstract
ENVASARC: A pivotal trial of envafolimab and envafolimab in combination with ipilimumab in patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy.Org: Duke Cancer Institute, Duke University Medical Center, Sarcoma Oncology Center, Department of Sarcoma, H. Lee Moffitt Cancer Center and Research Institute, Royal Marsden Hospital and Institute of Cancer Research,
Abstract
Camrelizumab combined with tyrosine kinase inhibitors in the treatment of patients with advanced renal cell carcinoma: A single-center prospective exploratory study.Org: Rare Tumors Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Huaiyin District Jinan, China, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China,
Abstract
Retrospective analysis of the multikinase inhibitor (MKI) pazopanib in differentiated thyroid carcinoma (DTC) in the beyond-first-line setting.Org: Mayo Clinic, University of Missouri–Kansas City, Mayo Clinic Florida,
Abstract
A novel prognostic model for oligometastatic renal cell carcinoma: COMPARZ study post-hoc analysis.Org: Fudan University Zhongshan Hospital, Department of Urology Surgery, Fudan University Shanghai Cancer Center, Shanghai, China, Fudan University Shanghai Cancer Center, Novartis Oncology, Novartis China,
Abstract
Clear cell sarcoma: The OSU experience.Org: The Ohio State University - James Cancer Hospital, The Ohio State University Medical Center, The Ohio State University James Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, Ohio State University Wexner Medical Center,